

Reference number(s)

532-A

Initial Prior Authorization Multaq

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Multaq	dronedarone

Indications

FDA-Approved Indications

Multaq is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF).

Coverage Criteria

Atrial Fibrillation (AF)

Authorization may be granted when the requested drug is being prescribed to reduce the risk of hospitalization for atrial fibrillation (AF) in a patient with a history of paroxysmal or persistent AF, i.e., non-permanent AF.

Multaq PA 532-A P05-2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Duration of Approval (DOA)

• 532-A: DOA: 12 months

References

- 1. Multaq [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; May 2024.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. https://online.lexi.com. Accessed April 18, 2025.
- 3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 04/18/2025).